SCHEMBL5544663

SCHEMBL5544663

[CH2]c1ncsc1-c1ccc(F)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DPP4 P27487 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
RIPK2 O43353 1/20 0.34
MGAM O43451 2/20 0.33
GAA P10253 2/20 0.33
SI P14410 2/20 0.33
MGAM2 Q2M2H8 2/20 0.33
ESR1 P03372 1/20 0.33
MAPT P10636 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
AGER Q15109 2/20 0.32
CLK1 P49759 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544666 0.79 NPC1 (0.39) KMONPC1RAB9AMEN1KMT2A
SCHEMBL2092932 0.79 MPL (0.40) NPC1RAB9AADORA2AADORA1GAA
SCHEMBL9586956 0.74 KDM4E (0.51) KMONPC1RAB9AMEN1KMT2A
SCHEMBL10432292 0.71 KMO (0.42) KMONPC1RAB9AMEN1KMT2A
SCHEMBL9586052 0.68 NPC1 (0.51) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL9135463 0.67 ALDH1A1 (0.52) KMOMEN1KMT2AESR1
SCHEMBL6629564 0.64 F2RL1 (0.50) KMONPC1RAB9AMEN1KMT2A
SCHEMBL28286611 0.64 GABRG2 (0.37) KMONPC1RAB9AMEN1KMT2A
SCHEMBL5912405 0.64 F2RL1 (0.51) KMONPC1RAB9AMEN1KMT2A
SCHEMBL28273968 0.64 CYP11B1 (0.43) MEN1KMT2ARIPK2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMO 4404/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.